FIGARO-DKD
Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease
Patient / Population Intervention / Exposure Comparison Outcome
In 7,437 patients with type 2 diabetes and CKD, finerenone reduced the cardiovascular composite compared with placebo.
N
7,437
Design
Double-blind RCT, median 3.4-year follow-up
Endpoint
CV death, MI, stroke or HF hospitalisation
Relevance
2
Result12.4% vs 14.2%; HR 0.87 (95% CI 0.76–0.98; p=0.03).
Pitt B, et al. N Engl J Med. 2021;385(24):2252-2263. 10.1056/NEJMoa2110956
Discussion & critique
Confirmed the cardiovascular benefit of finerenone across the milder end of the CKD spectrum; pooled with FIDELIO in the FIDELITY analysis.